IN188924B - - Google Patents

Info

Publication number
IN188924B
IN188924B IN217MU2001A IN188924B IN 188924 B IN188924 B IN 188924B IN 217MU2001 A IN217MU2001 A IN 217MU2001A IN 188924 B IN188924 B IN 188924B
Authority
IN
India
Prior art keywords
compositions
amphotericin
autoclaving
phospholipids
sterilized
Prior art date
Application number
Other languages
English (en)
Inventor
Srikanth Annappa Pai
Sangeeta Hanurmesh Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd
Priority to IN217MU2001 priority Critical patent/IN188924B/en
Priority to BR0116922-0A priority patent/BR0116922A/pt
Priority to MXPA03007777A priority patent/MXPA03007777A/es
Priority to AU2001250643A priority patent/AU2001250643B2/en
Priority to PCT/IN2001/000040 priority patent/WO2002069983A1/en
Priority to DK01923963T priority patent/DK1368041T3/da
Priority to CA002438847A priority patent/CA2438847A1/en
Priority to CZ20032264A priority patent/CZ20032264A3/cs
Priority to US10/469,624 priority patent/US20040137049A1/en
Priority to ES01923963T priority patent/ES2227172T3/es
Priority to CNB018231632A priority patent/CN1255114C/zh
Priority to EP01923963A priority patent/EP1368041B1/en
Priority to YU75403A priority patent/YU75403A/sh
Priority to NZ528281A priority patent/NZ528281A/en
Priority to AT01923963T priority patent/ATE274913T1/de
Priority to SK1074-2003A priority patent/SK10742003A3/sk
Priority to PT01923963T priority patent/PT1368041E/pt
Priority to JP2002569158A priority patent/JP2004523566A/ja
Priority to DE60105322T priority patent/DE60105322T2/de
Priority to KR1020037011489A priority patent/KR100810067B1/ko
Priority to EA200300948A priority patent/EA006241B1/ru
Publication of IN188924B publication Critical patent/IN188924B/en
Priority to ZA200307307A priority patent/ZA200307307B/en
Priority to BG108188A priority patent/BG108188A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IN217MU2001 2001-03-01 2001-03-01 IN188924B (da)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (da) 2001-03-01 2001-03-01
AU2001250643A AU2001250643B2 (en) 2001-03-01 2001-03-16 Amphotericin B aqueous composition
JP2002569158A JP2004523566A (ja) 2001-03-01 2001-03-16 アンホテリシンｂ水性組成物
EP01923963A EP1368041B1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition
PCT/IN2001/000040 WO2002069983A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition
DK01923963T DK1368041T3 (da) 2001-03-01 2001-03-16 Vandigt amphotericin B-præparat
CA002438847A CA2438847A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition
CZ20032264A CZ20032264A3 (cs) 2001-03-01 2001-03-16 Vodná kompozice Amphotericinu B
US10/469,624 US20040137049A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition
ES01923963T ES2227172T3 (es) 2001-03-01 2001-03-16 Composicion acuosa de anfotericina b.
NZ528281A NZ528281A (en) 2001-03-01 2001-03-16 Amphotericin B aqueous composition and a process for preparing the same
BR0116922-0A BR0116922A (pt) 2001-03-01 2001-03-16 Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila
YU75403A YU75403A (sh) 2001-03-01 2001-03-16 Vodeni amfotericin b preparat
CNB018231632A CN1255114C (zh) 2001-03-01 2001-03-16 两性霉素b的水性组合物
AT01923963T ATE274913T1 (de) 2001-03-01 2001-03-16 Wässerige zusammensetzung enthaltend amphotericin b
SK1074-2003A SK10742003A3 (sk) 2001-03-01 2001-03-16 Vodná kompozícia amfotericínu B
PT01923963T PT1368041E (pt) 2001-03-01 2001-03-16 Composicao aquosa de anfotericina
MXPA03007777A MXPA03007777A (es) 2001-03-01 2001-03-16 Composicion acuosa de anfotericina b.
DE60105322T DE60105322T2 (de) 2001-03-01 2001-03-16 Wässerige zusammensetzung enthaltend amphotericin b
KR1020037011489A KR100810067B1 (ko) 2001-03-01 2001-03-16 암포테리신 ｂ 수성 조성물
EA200300948A EA006241B1 (ru) 2001-03-01 2001-03-16 Водная композиция амфотерицина b
ZA200307307A ZA200307307B (en) 2001-03-01 2003-09-18 Amphotericin B aqueous composition.
BG108188A BG108188A (bg) 2001-03-01 2003-09-23 Воден състав на амфотерицин в

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (da) 2001-03-01 2001-03-01

Publications (1)

Publication Number Publication Date
IN188924B true IN188924B (da) 2002-11-23

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
IN217MU2001 IN188924B (da) 2001-03-01 2001-03-01

Country Status (23)

Country Link
US (1) US20040137049A1 (da)
EP (1) EP1368041B1 (da)
JP (1) JP2004523566A (da)
KR (1) KR100810067B1 (da)
CN (1) CN1255114C (da)
AT (1) ATE274913T1 (da)
AU (1) AU2001250643B2 (da)
BG (1) BG108188A (da)
BR (1) BR0116922A (da)
CA (1) CA2438847A1 (da)
CZ (1) CZ20032264A3 (da)
DE (1) DE60105322T2 (da)
DK (1) DK1368041T3 (da)
EA (1) EA006241B1 (da)
ES (1) ES2227172T3 (da)
IN (1) IN188924B (da)
MX (1) MXPA03007777A (da)
NZ (1) NZ528281A (da)
PT (1) PT1368041E (da)
SK (1) SK10742003A3 (da)
WO (1) WO2002069983A1 (da)
YU (1) YU75403A (da)
ZA (1) ZA200307307B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
WO2013142184A1 (en) * 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3222324B1 (en) 2016-03-23 2020-05-13 Wayne State University Valproate as a topical anti-fungal treatment
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
BR0116922A (pt) 2004-04-27
YU75403A (sh) 2006-05-25
JP2004523566A (ja) 2004-08-05
EP1368041B1 (en) 2004-09-01
PT1368041E (pt) 2005-01-31
MXPA03007777A (es) 2003-12-08
NZ528281A (en) 2006-11-30
CN1255114C (zh) 2006-05-10
DE60105322T2 (de) 2005-09-15
WO2002069983A1 (en) 2002-09-12
CA2438847A1 (en) 2002-09-12
KR20040018337A (ko) 2004-03-03
DK1368041T3 (da) 2005-01-17
SK10742003A3 (sk) 2004-01-08
DE60105322D1 (de) 2004-10-07
CN1505519A (zh) 2004-06-16
EP1368041A1 (en) 2003-12-10
ES2227172T3 (es) 2005-04-01
EA006241B1 (ru) 2005-10-27
KR100810067B1 (ko) 2008-03-05
ATE274913T1 (de) 2004-09-15
US20040137049A1 (en) 2004-07-15
EA200300948A1 (ru) 2004-04-29
CZ20032264A3 (cs) 2003-12-17
BG108188A (bg) 2004-09-30
AU2001250643B2 (en) 2007-03-22
ZA200307307B (en) 2004-04-20

Similar Documents

Publication Publication Date Title
IN188924B (da)
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
CA2292359A1 (en) Novel azalides and methods of making same
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
SI1458360T1 (sl) Pulmonalno dajanje aminoglikozidov
EP1075837A3 (en) Process for the preparation of aqueous formulations for ophthalmic use
LU91908I2 (fr) Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®)
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2004056828A3 (en) Novel compounds and uses thereof
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
CY1110664T1 (el) Ενδορινικες συνθεσετς
MXPA03010761A (es) Combinaciones farmaceuticas.
TW200502231A (en) Prodrugs of proton pump inhibitors
MXPA04006041A (es) Antivirales de piridoquinoxalina.
WO2003090744A8 (en) Antibacterial compositions comprising metal phthalocyanine analogues
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
NO20074167L (no) Peptidiske forbindelser
WO2002072581A3 (en) Pyrazolopyriadine derivatives
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv
PT1157688E (pt) Formulacoes oftalmicas aquosas antibacterianas contendo ofloxacina e quitosano
WO2002057281A3 (en) Aminoglycosides as antibiotics